145 related articles for article (PubMed ID: 33380869)
1. Presenting stage and risk group in men dying of prostate cancer.
Parimi S; Bondy S; Aparicio M; Sunderland K; Cho J; Bachand F; Nguyen Chi K; Pickles T; Tyldesley S
Curr Oncol; 2020 Dec; 27(6):e547-e551. PubMed ID: 33380869
[TBL] [Abstract][Full Text] [Related]
2. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic characteristics of lethal prostate cancer.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Brasso K; Vainer B; Iversen P
Eur J Cancer; 2017 Oct; 84():18-26. PubMed ID: 28779631
[TBL] [Abstract][Full Text] [Related]
4. Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer.
Man A; Pickles T; Chi KN;
J Urol; 2003 Sep; 170(3):901-4. PubMed ID: 12913726
[TBL] [Abstract][Full Text] [Related]
5. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
6. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
7. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
[TBL] [Abstract][Full Text] [Related]
8. Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.
Huynh-Le MP; Myklebust TÅ; Feng CH; Karunamuni R; Johannesen TB; Dale AM; Andreassen OA; Seibert TM
Cancer; 2020 Apr; 126(8):1691-1699. PubMed ID: 31899813
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
11. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
13. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
16. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
17. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
Stattin P; Holmberg E; Johansson JE; Holmberg L; Adolfsson J; Hugosson J;
J Natl Cancer Inst; 2010 Jul; 102(13):950-8. PubMed ID: 20562373
[TBL] [Abstract][Full Text] [Related]
19. Contemporary national trends in prostate cancer risk profile at diagnosis.
Fletcher SA; von Landenberg N; Cole AP; Gild P; Choueiri TK; Lipsitz SR; Trinh QD; Kibel AS
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):81-87. PubMed ID: 31235801
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
